Affinity Asset Advisors 13F annual report

Affinity Asset Advisors is an investment fund managing more than $474 billion ran by Jonathan Chu. There are currently 70 companies in Mr. Chu’s portfolio. The largest investments include Immunogen and Cerevel Therapeutics Hldng I, together worth $73.4 billion.

$474 billion Assets Under Management (AUM)

As of 6th February 2024, Affinity Asset Advisors’s top holding is 1,404,608 shares of Immunogen currently worth over $41.6 billion and making up 8.8% of the portfolio value. Relative to the number of outstanding shares of Immunogen, Affinity Asset Advisors owns more than approximately 0.1% of the company. In addition, the fund holds 750,000 shares of Cerevel Therapeutics Hldng I worth $31.8 billion. The third-largest holding is Cymabay Therapeutics Inc worth $25.8 billion and the next is Madrigal Pharmaceuticals Inc worth $23.1 billion, with 100,000 shares owned.

Currently, Affinity Asset Advisors's portfolio is worth at least $474 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Affinity Asset Advisors

The Affinity Asset Advisors office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Jonathan Chu serves as the Chief Compliance Officer at Affinity Asset Advisors.

Recent trades

In the most recent 13F filing, Affinity Asset Advisors revealed that it had opened a new position in Immunogen and bought 1,404,608 shares worth $41.6 billion. This means they effectively own approximately 0.1% of the company. Immunogen makes up 14.0% of the fund's Health Care sector allocation and has grown its share price by 617.9% in the past year.

The investment fund also strengthened its position in Cerevel Therapeutics Hldng I by buying 200,000 additional shares. This makes their stake in Cerevel Therapeutics Hldng I total 750,000 shares worth $31.8 billion.

On the other hand, there are companies that Affinity Asset Advisors is getting rid of from its portfolio. Affinity Asset Advisors closed its position in Chinook Therapeutics on 13th February 2024. It sold the previously owned 321,017 shares for $12.3 billion. Jonathan Chu also disclosed a decreased stake in Autolus Therapeutics plc by approximately 0.1%. This leaves the value of the investment at $9.98 billion and 1,550,408 shares.

One of the average hedge funds

The two most similar investment funds to Affinity Asset Advisors are Mraz, Amerine & Associates and Townsend & Associates, Inc. They manage $474 billion and $474 billion respectively.


Jonathan Chu investment strategy

Affinity Asset Advisors’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 62.8% of the total portfolio value. The fund focuses on investments in the United States as 50.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 4% of the total holdings value. On the other hand, large-cap stocks make up only 2.9% of the portfolio. The average market cap of the portfolio companies is close to $6.66 billion.

The complete list of Affinity Asset Advisors trades based on 13F SEC filings

These positions were updated on February 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Immunogen, Inc.
Opened
1,404,608
$41,646,627,000 8.79%
Cerevel Therapeutics Hldng I
36.36%
750,000
$31,800,000,000 6.71%
Cymabay Therapeutics Inc
3.84%
1,090,441
$25,756,216,000 5.43%
Madrigal Pharmaceuticals Inc
8.11%
100,000
$23,138,000,000 4.88%
Xenon Pharmaceuticals Inc
661.89%
460,000
$21,187,600,000 4.47%
Teva Pharmaceutical Inds Ltd
18.75%
1,900,000
$19,836,000,000 4.19%
Arcellx Inc
50.26%
340,000
$18,870,000,000 3.98%
Lianbio
372.06%
3,779,694
$16,895,232,000 3.56%
Crinetics Pharmaceuticals In
Opened
447,095
$15,907,640,000 3.36%
Celldex Therapeutics Inc.
359.61%
400,000
$15,864,000,000 3.35%
Apogee Therapeutics Inc
Opened
537,093
$15,006,378,000 3.17%
Immunovant Inc
32.69%
345,000
$14,534,850,000 3.07%
Cytokinetics Inc
27.85%
160,000
$13,358,400,000 2.82%
Nuvalent Inc
Opened
175,000
$12,878,250,000 2.72%
Chinook Therapeutics, Inc.
Closed
321,017
$12,333,473,000
Biogen Inc
Closed
40,000
$11,394,000,000
Astria Therapeutics Inc
125.31%
1,466,465
$11,262,451,000 2.38%
Verona Pharma Plc
25.95%
563,824
$11,208,821,000 2.36%
Spyre Therapeutics Inc
Opened
517,554
$11,137,762,000 2.35%
Autolus Therapeutics plc
2.43%
1,550,408
$9,984,628,000 2.11%
Alkermes plc
Opened
356,384
$9,886,092,000 2.09%
Inozyme Pharma, Inc.
150.84%
1,885,802
$8,033,517,000 1.69%
Nurix Therapeutics, Inc.
590.11%
690,112
$7,121,956,000 1.50%
Prothena Corp Plc
Closed
100,000
$6,828,000,000
Centessa Pharmaceuticals Plc
11.66%
795,729
$6,334,003,000 1.34%
Establishment Labs Holdings Inc
7.88%
228,277
$5,910,092,000 1.25%
Mirati Therapeutics Inc
Opened
100,049
$5,877,879,000 1.24%
Roivant Sciences Ltd
Opened
500,000
$5,615,000,000 1.18%
Viking Therapeutics Inc
No change
300,000
$5,583,000,000 1.18%
Savara Inc
Opened
1,150,000
$5,405,000,000 1.14%
COMPASS Pathways plc
Opened
550,000
$4,812,500,000 1.02%
Apellis Pharmaceuticals Inc
650.00%
75,000
$4,489,500,000 0.95%
Moonlake Immunotherapeutics
Opened
70,988
$4,286,965,000 0.90%
Dynavax Technologies Corp.
Opened
300,000
$4,194,000,000 0.88%
Astrazeneca plc
No change
60,000
$4,041,000,000 0.85%
Axsome Therapeutics Inc
300.00%
50,000
$3,979,500,000 0.84%
SpringWorks Therapeutics, Inc.
23.08%
100,000
$3,650,000,000 0.77%
Relay Therapeutics, Inc.
Opened
300,000
$3,303,000,000 0.70%
Ventyx Biosciences Inc
Closed
100,696
$3,302,829,000
BridgeBio Pharma Inc
127.71%
80,000
$3,229,600,000 0.68%
Krystal Biotech Inc
Opened
25,000
$3,101,500,000 0.65%
Cullinan Oncology, LLC
Opened
300,000
$3,057,000,000 0.64%
Tango Therapeutics Inc
Opened
300,274
$2,972,713,000 0.63%
Reata Pharmaceuticals Inc
Closed
29,105
$2,967,546,000
Argenx Se
Opened
7,500
$2,853,225,000 0.60%
Kura Oncology Inc
78.96%
191,535
$2,754,273,000 0.58%
FibroGen Inc
Closed
983,300
$2,654,910,000
EyePoint Pharmaceuticals Inc
Opened
109,900
$2,539,789,000 0.54%
Ascendis Pharma A/S
65.37%
20,000
$2,519,000,000 0.53%
Mersana Therapeutics Inc
Opened
1,000,000
$2,320,000,000 0.49%
Theseus Pharmaceuticals Inc
Closed
240,244
$2,241,477,000
Aeglea BioTherapeutics Inc
Closed
4,900,000
$2,207,450,000
Immatics N.v
33.33%
200,000
$2,106,000,000 0.44%
Vincerx Pharma Inc
Closed
1,492,771
$1,940,602,000
Penumbra Inc
Opened
7,500
$1,886,550,000 0.40%
Tourmaline Bio Inc
Opened
68,081
$1,782,361,000 0.38%
ADC Therapeutics SA
68.92%
1,013,540
$1,682,476,000 0.35%
Cabaletta Bio Inc
Closed
125,000
$1,613,750,000
Vaxcyte, Inc.
79.56%
25,000
$1,570,000,000 0.33%
KalVista Pharmaceuticals Inc
29.35%
125,969
$1,543,120,000 0.33%
Mirum Pharmaceuticals Inc
66.67%
50,000
$1,476,000,000 0.31%
Newamsterdam Pharma Company
25.00%
125,000
$1,396,250,000 0.29%
Neurocrine Biosciences, Inc.
Opened
10,000
$1,317,600,000 0.28%
Inari Med Inc
Opened
20,000
$1,298,400,000 0.27%
Allogene Therapeutics Inc
Opened
400,000
$1,284,000,000 0.27%
Aadi Bioscience Inc
Closed
187,675
$1,283,697,000
Aldeyra Therapeutics Inc
Closed
150,000
$1,258,500,000
Morphic Hldg Inc
78.86%
42,670
$1,232,310,000 0.26%
Alpine Immune Sciences Inc
Closed
118,891
$1,222,199,000
Viridian Therapeutics Inc
Opened
50,000
$1,089,000,000 0.23%
Mineralys Therapeutics Inc
Closed
62,500
$1,065,625,000
BioAtla, Inc.
Closed
325,000
$975,000,000
Biohaven Ltd
Opened
20,866
$893,065,000 0.19%
Puma Biotechnology Inc
No change
202,349
$876,171,000 0.18%
Milestone Pharmaceuticals In
Closed
300,068
$855,194,000
Fulcrum Therapeutics Inc
Opened
125,000
$843,750,000 0.18%
AvroBio Inc
Opened
500,000
$680,000,000 0.14%
Jasper Therapeutics Inc
Closed
476,948
$653,419,000
Talaris Therapeutics Inc
Closed
200,000
$608,000,000
Immatics N.v
Opened
187,204
$546,636,000 0.12%
Vir Biotechnology Inc
Closed
20,000
$490,600,000
Spdr S&p 500 Etf Tr
Closed
18,087
$488,256,000
Nls Pharmaceutics Ltd
Closed
400,000
$440,000,000
Newamsterdam Pharma Company
Opened
137,000
$428,810,000 0.09%
Terns Pharmaceuticals Inc
Opened
66,000
$428,340,000 0.09%
Nuvation Bio Inc
No change
250,000
$377,500,000 0.08%
Context Therapeutics Inc
22.89%
328,817
$371,563,000 0.08%
Inflarx Nv
16.70%
200,097
$326,158,000 0.07%
Promis Neurosciences Inc
Opened
265,958
$305,852,000 0.06%
Aravive Inc
Opened
346,511
$42,863,000 0.01%
Rocket Pharmaceuticals Inc
Opened
75,000
$36,750,000 0.01%
No transactions found
Showing first 500 out of 91 holdings